| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IPI LEGACY LIQUIDATION Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,020 | -20,47 % | Medigene: Zurückziehung - 18.11.2025 | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| OCUGEN | 1,414 | -0,56 % | Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk | ||
| VIKING THERAPEUTICS | 28,050 | +0,18 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,508 | -0,45 % | Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors | BERKELEY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber (the "Company" or "Quantum Cyber"), today announced a strategic update in response... ► Artikel lesen | |
| INFLARX | 1,271 | +0,32 % | SCHOCKMELDUNG bei InflaRx NV: Warum Sie jetzt genau hinschauen sollten - Die Chance die sich zum Wochenstart ergibt! | ||
| CARDIOL THERAPEUTICS | 1,200 | +0,67 % | Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley - Cardiol Therapeutics | ||
| IBIO | 1,439 | +0,07 % | iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600 | ||
| REDHILL BIOPHARMA | 1,025 | +1,49 % | RedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of... ► Artikel lesen | |
| ATAIBECKLEY | 3,880 | -2,02 % | Trader-Interview mit Bastian Galuschka SAP, BASF, ATAIBeckley, Kalvista, MarvellTechnology, Echostar | In dieser Ausgabe des Trader-Interviews analysieren Lothar Albert und Bastian Galuschka die aktuelle Börsenlage und beleuchten ausgewählte Einzelwerte mit speziellem Fokus auf technische Signale, fundamentale... ► Artikel lesen | |
| ALDEYRA | 1,360 | +2,26 % | Aldeyra Therapeutics: Aufsichtsratsmitglied Martin J. Joyce tritt nicht zur Wiederwahl an | ||
| OCULAR THERAPEUTIX | 8,100 | 0,00 % | Ocular Therapeutix, Inc.: Ocular Therapeutix to Host Investor Day on June 17, 2026 | ||
| CAPRICOR | 29,250 | -2,82 % | Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting | ||
| ARDELYX | 5,070 | -0,20 % | Ardelyx, Inc.: Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026 | ||
| AKEBIA | 1,239 | +1,14 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors | CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics- , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen |